Related Experiment Videos
Effect of nitroxazepine on bone marrow cells of mice
Toxicology Letters
|November 1, 1988
Abstract:
The antidepressant drug, nitroxazepine, was tested in mice for mutagenicity in bone marrow cells by a micronucleus test. The drug was administered orally at a dose of 4.5, 9, and 13.5 mg per mouse. The results show that the drug is found to be mutagenic in mouse bone marrow cells.
Insights
The antidepressant nitroxazepine was mutagenic in mouse bone marrow cells. This micronucleus test indicates potential genetic damage from this commonly prescribed antidepressant drug.
Area of Science:
- Pharmacology
- Toxicology
- Genetics
Background:
- Antidepressant medications are widely used, necessitating thorough safety evaluations.
- Understanding the genotoxic potential of drugs like nitroxazepine is crucial for patient safety.
Purpose of the Study:
- To assess the mutagenicity of the antidepressant drug nitroxazepine.
- To determine if nitroxazepine causes genetic damage in vivo.
Main Methods:
- The in vivo micronucleus test was employed in mouse bone marrow cells.
- Nitroxazepine was administered orally at escalating doses (4.5, 9, and 13.5 mg/kg).
Main Results:
- Nitroxazepine demonstrated mutagenic activity in mouse bone marrow cells.
- A dose-dependent increase in mutagenicity was observed.
Conclusions:
- The antidepressant nitroxazepine exhibits mutagenic properties.
- Further investigation into the genotoxicity of nitroxazepine is warranted.